Gilead Surges On HIV In Q3, But Investors Pull Back With Myogen Purchase
The strength of Gilead's HIV portfolio, and particularly its newest addition Atripla, drew investor confidence in the third quarter, with the biopharmaceutical firm gaining 16.2% to reach a quarterly high close of 68.77 Sept. 29
You may also be interested in...
Gilead Sciences beat Encysive Pharmaceuticals in a race to bring a second endothelin receptor antagonist to market for the treatment of pulmonary arterial hypertension after FDA simultaneously granted approval to Gilead's Letairis and delayed approval of Encysive's Thelin June 15
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.